Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

Prostate. 2000 Jan;42(1):34-44. doi: 10.1002/(sici)1097-0045(20000101)42:1<34::aid-pros5>3.0.co;2-2.

Abstract

Background: Androgen-independent growth leads to progressive prostate cancer after androgen-ablation therapy. This may be caused by altered specificity of the androgen receptor (AR), by ligand-independent stimulation of the AR, or by paracrine growth modulation by neuropeptides secreted by neuroendocrine (NE) cells.

Methods: We established and characterized the androgen-independent FGC-DCC from the androgen-dependent LNCaP fast growing colony (FGC) cell line. The androgen-independent DU-145, FGC-DCC, and PC-3, and the androgen-dependent LNCaP and PC-346C cell lines were used to study growth modulation of gastrin-releasing peptide (GRP), calcitonin (CT), serotonin (5-HT), and vasoactive intestinal peptide (VIP) by (3)H-thymidine incorporation. Specificity of the growth-modulating effects was tested with the anti-GRP monoclonal antibody 2A11 and induction of cAMP by neuropeptides.

Results: Androgen-independent growth stimulation by neuropeptides was shown in DU-145 and PC-346C. 2A11 inhibited GRP-induced (3)H-thymidine incorporation in DU-145 and PC-346C and inhibited proliferation of the FGC-DCC and PC-3 cell lines. With some exceptions, cAMP induction paralleled growth stimulation. Dideoxyadenosine (DDA) inhibited the GRP-induced growth effect in DU-145 and PC-346C, whereas oxadiazoloquinoxaline-1-one (ODQ) had no effect on (3)H-thymidine incorporation. None of the neuropeptides stimulated growth of LNCaP, FGC-DCC, or PC-3.

Conclusions: GRP-induced growth of DU-145 and PC-346C was specific and cAMP-mediated. Androgen-independent growth of FGC-DCC cells was mainly due to an induction of Bcl-2 expression and possibly through the activation of an autocrine and NE-like pathway, as has been shown also for the PC-3 cell line. Growth induction of non-NE cells by neuropeptides could be a possible role for NE cells in clinical prostate cancer.

MeSH terms

  • Androgens / physiology*
  • Cell Division / drug effects
  • Cyclic AMP / physiology
  • Dideoxyadenosine / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Gastrin-Releasing Peptide / pharmacology
  • Humans
  • Male
  • Neuropeptides / physiology*
  • Oxadiazoles / pharmacology
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Quinoxalines / pharmacology
  • Thymidine / metabolism
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / pathology

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Androgens
  • Enzyme Inhibitors
  • Neuropeptides
  • Oxadiazoles
  • Proto-Oncogene Proteins c-bcl-2
  • Quinoxalines
  • Dideoxyadenosine
  • Gastrin-Releasing Peptide
  • Cyclic AMP
  • Thymidine